Table 4. Amelioration of organomegaly... | American Society of Hematology

Table 4.

Amelioration of organomegaly

Treatment	No.mice	Recipient genotype	No. BM cells injected × 10⁶	Donor cells at necropsy, %	Spleen, % of body weight	Heart, % of body weight	Liver, % of body weight
BM	10	sph/sph	4.8 -6.0	0	5.31 ± 0.41^4-150	1.13 ± 0.07	6.79 ± 0.20
	3	sph/sph	4.8 -6.0	13 -26	4.13 ± 0.15^4-151	0.97 ± 0.03^4-151	5.80 ± 0.47
BM + PB	8	sph/sph	2.1 -11.9	0	5.61 ± 0.68	1.28 ± 0.13	6.28 ± 0.46
	5	sph/sph	2.1 -11.9	10 -25	3.96 ± 0.39^4-151	0.94 ± 0.01^4-151	6.31 ± 0.38
	3	sph/sph	2.1 -11.9	60 -100	3.40 ± 0.35^4-151	0.68 ± 0.02^‡	4.50 ± 0.15^4-151,^4-155
PB	9	sph/sph	(PB only)	0	5.03 ± 0.20	1.01 ± 0.09	6.52 ± 0.23
Uninjectedsph/sph	40^4-153	N/A	N/A	N/A	5.35 ± 0.14	1.19 ± 0.04	6.57 ± 0.15
Uninjected +/+	23^4-153	N/A	N/A	N/A	0.27 ± 0.01^4-151	0.42 ± 0.01^4-151	4.88 ± 0.20^4-151

Treatment	No.mice	Recipient genotype	No. BM cells injected × 10⁶	Donor cells at necropsy, %	Spleen, % of body weight	Heart, % of body weight	Liver, % of body weight
BM	10	sph/sph	4.8 -6.0	0	5.31 ± 0.41^4-150	1.13 ± 0.07	6.79 ± 0.20
	3	sph/sph	4.8 -6.0	13 -26	4.13 ± 0.15^4-151	0.97 ± 0.03^4-151	5.80 ± 0.47
BM + PB	8	sph/sph	2.1 -11.9	0	5.61 ± 0.68	1.28 ± 0.13	6.28 ± 0.46
	5	sph/sph	2.1 -11.9	10 -25	3.96 ± 0.39^4-151	0.94 ± 0.01^4-151	6.31 ± 0.38
	3	sph/sph	2.1 -11.9	60 -100	3.40 ± 0.35^4-151	0.68 ± 0.02^‡	4.50 ± 0.15^4-151,^4-155
PB	9	sph/sph	(PB only)	0	5.03 ± 0.20	1.01 ± 0.09	6.52 ± 0.23
Uninjectedsph/sph	40^4-153	N/A	N/A	N/A	5.35 ± 0.14	1.19 ± 0.04	6.57 ± 0.15
Uninjected +/+	23^4-153	N/A	N/A	N/A	0.27 ± 0.01^4-151	0.42 ± 0.01^4-151	4.88 ± 0.20^4-151

N/A indicates not applicable; for other abbreviations, see Table 2.

Mean ± SEM.

Significantly different from uninjected sph/sph,P ≤ .005.

Significantly different from uninjected sph/sphand from BM-plus-PB mice with 10% to 25% donor cells,P ≤ .0001.

Not significantly different from +/+.

Except for liver data, where n = 19 forsph/sph and n = 16 for +/+.